Brokerages Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) PT at $4.50

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has been given a consensus rating of “Hold” by the five ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $4.50.

A number of analysts have recently issued reports on the company. Barclays reiterated an “equal weight” rating and set a $1.00 target price (down previously from $5.00) on shares of Sangamo Therapeutics in a report on Friday, November 7th. Wall Street Zen lowered shares of Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Sangamo Therapeutics in a research note on Wednesday, October 8th.

Institutional Investors Weigh In On Sangamo Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. World Investment Advisors boosted its stake in shares of Sangamo Therapeutics by 88.5% in the third quarter. World Investment Advisors now owns 42,611 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 20,000 shares during the period. Golden State Equity Partners boosted its position in Sangamo Therapeutics by 5.4% in the 2nd quarter. Golden State Equity Partners now owns 391,943 shares of the biopharmaceutical company’s stock valued at $212,000 after buying an additional 20,000 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of Sangamo Therapeutics by 30.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 90,550 shares of the biopharmaceutical company’s stock valued at $48,000 after acquiring an additional 21,300 shares in the last quarter. Wealth Management Associates Inc. increased its position in shares of Sangamo Therapeutics by 9.1% during the third quarter. Wealth Management Associates Inc. now owns 335,800 shares of the biopharmaceutical company’s stock worth $226,000 after acquiring an additional 28,000 shares during the last quarter. Finally, Boothbay Fund Management LLC lifted its stake in shares of Sangamo Therapeutics by 10.8% in the third quarter. Boothbay Fund Management LLC now owns 353,292 shares of the biopharmaceutical company’s stock worth $238,000 after acquiring an additional 34,473 shares in the last quarter. Hedge funds and other institutional investors own 56.92% of the company’s stock.

Sangamo Therapeutics Stock Up 1.4%

SGMO stock opened at $0.45 on Friday. The company has a market cap of $151.08 million, a price-to-earnings ratio of -1.02 and a beta of 1.29. The business has a fifty day simple moving average of $0.45 and a 200-day simple moving average of $0.53. Sangamo Therapeutics has a 52 week low of $0.38 and a 52 week high of $1.40.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.08). The firm had revenue of $0.58 million during the quarter, compared to analyst estimates of $34.40 million. Sangamo Therapeutics had a negative net margin of 331.28% and a negative return on equity of 813.95%. As a group, analysts expect that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.